Loading
Eicosanoids and Hypertension Pharmacology · Journal article
Acs Omega · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study exploring crocetin as a putative CYP2J2 inhibitor using computational, biochemical, and in vivo mouse models of breast cancer. The work proposes a novel pathway linking CYP2J2/EET axis disruption to antitumor effects but provides no clinical evidence or quantified efficacy data suitable for translation.
Preclinical mechanistic study combining in silico molecular docking and dynamics simulation, in vitro enzyme inhibition assays, and in vivo mouse model investigation.. BALB/c mice bearing breast cancer; human and mouse liver microsomes; no human subjects enrolled.. Intervention: Crocetin, a phyto-based molecule proposed as a CYP2J2 inhibitor.. Compared with: Not explicitly stated; rivaroxaban used as a CYP2J2 substrate probe rather than a therapeutic comparator..
In vitro mechanistic investigations using human liver microsomes indicate crocetin acts as a specific and reversible CYP2J2 inhibitor. In vivo crocetin treatment enhanced plasma exposure of rivaroxaban (CYP2J2 substrate) in BALB/c mice by delaying metabolism. In vivo crocetin attenuated CYP2J2 protein expression in mouse liver tissues.
Mouse model findings do not guarantee human efficacy or safety.
This work is exploratory and does not yet provide evidence for clinical use. It identifies a potential therapeutic target and mechanism but requires further validation in clinical trials before informing practice.
Mechanistic and exploratory preclinical work using in silico, in vitro, and in vivo models to propose a novel pathway; no clinical trial data, no hard clinical endpoints, and findings remain at proof-of-concept stage.
As stated by the source record.
This work is exploratory and does not yet provide evidence for clinical use. It identifies a potential therapeutic target and mechanism but requires further validation in clinical trials before informing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract CYP2J2 catalyzes the conversion of arachidonic acid into epoxyeicosatrienoic acids (EET), which have gained significant attention due to their oncogenic properties. Differential overexpression of CYP2J2 in tumors results in increased EET production. The role of EET in tumorigenesis is quite clear, but inhibition of CYP2J2 on EET formation with its molecular target is poorly understood. Research is ongoing to identify CYP2J2 inhibitors and the role of the CYP2J2/EET axis in halting tumorigenesis. In these contexts, we aimed to address the same through in silico, in vitro, and in vivo approaches using crocetin, a phyto-based druggable molecule. In vitro mechanistic investigations using human liver microsomes (HLM) indicate that crocetin could act as a specific and reversible CYP2J2 inhibitor. In silico molecular docking analysis and molecular dynamics (MD) simulation explicate strong and stable interactions between crocetin and active site of human CYP2J2. In vivo investigations in BALB/c mice reveal that crocetin could enhance the plasma exposure of rivaroxaban (CYP2J2 substrate) by delaying metabolism and attenuating CYP2J2 protein expression in the liver tissues. Additionally, in vitro studies using HLM and mouse liver microsomes (MLM) suggest that crocetin could substantially hinder EET formation. Thereafter, crocetin showcases its antitumor effect in the mouse model of breast cancer involving downregulation of CYP2J2 expression and impediment of EET formation in the tumor tissues. Further, proteomics data from crocetin-treated tumor tissues with gene ontology analysis (KEGG database) reflect upregulation/downregulation of key proteins and biological processes associated with attenuating tumorigenesis. It is a footstep toward understanding the CYP2J2/EET axis for targeted breast cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.